Published in Br J Haematol on May 01, 1999
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res (2013) 2.00
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
An overview of the vaccinia virus infectome: a survey of the proteins of the poxvirus-infected cell. J Virol (2011) 0.85
Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML. Br J Cancer (2001) 0.76
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes (2006) 2.28
Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood (1994) 2.11
Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol (1996) 2.05
Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia (2007) 1.97
Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia (2000) 1.91
Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection. Transfusion (2000) 1.85
The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol (1991) 1.81
Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia (2004) 1.77
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia (2008) 1.76
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia (2004) 1.71
Combination chemotherapy with CHOP for recurrent thrombotic thrombocytopenic purpura. Br J Haematol (1997) 1.71
Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia (2008) 1.70
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol (1998) 1.68
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia (2010) 1.65
Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia (2008) 1.62
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia (2013) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer (2001) 1.53
Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg (1991) 1.53
A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones (2001) 1.52
Sleep disruption alters nocturnal ACTH and cortisol secretory patterns. Biol Psychiatry (1991) 1.51
[Ethics in medicine: needs and forms]. Internist (Berl) (1999) 1.51
Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia (2011) 1.45
New insights into the biology of Philadelphia-chromosome-positive acute lymphoblastic leukaemia using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Br J Haematol (1997) 1.43
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia (2012) 1.42
Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet (1984) 1.42
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
[Paraneoplastic syndromes]. Internist (Berl) (1994) 1.40
Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity. Leukemia (2009) 1.40
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia (2006) 1.40
Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol (2003) 1.36
Landscape of TET2 mutations in acute myeloid leukemia. Leukemia (2011) 1.35
Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood (2001) 1.34
Treatment of primary, recurrent or inadequately resected high-risk soft-tissue sarcomas (STS) of adults: results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer (2001) 1.32
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia (2005) 1.32
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia (2011) 1.31
Hsp70 plasma membrane expression on primary tumor biopsy material and bone marrow of leukemic patients. Cell Stress Chaperones (2000) 1.28
AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia (2009) 1.27
The selfish brain: competition for energy resources. Prog Brain Res (2006) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
Management of acute myeloid leukemia in elderly patients. J Clin Oncol (1999) 1.25
Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur J Haematol (2001) 1.25
Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia (2007) 1.22
Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol (2001) 1.21
Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood (1995) 1.20
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia (2007) 1.18
Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia (2011) 1.18
Molecular analysis of the CALM/AF10 fusion: identical rearrangements in acute myeloid leukemia, acute lymphoblastic leukemia and malignant lymphoma patients. Leukemia (2000) 1.18
Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood (2001) 1.17
Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol (1985) 1.12
Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia (2005) 1.12
Obese men respond to cognitive but not to catabolic brain insulin signaling. Int J Obes (Lond) (2007) 1.11
Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif (2007) 1.10
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia (2005) 1.09
S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol (1997) 1.09
Low cerebrospinal fluid insulin levels in obese humans. Diabetologia (2006) 1.08
High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia (2009) 1.07
Plasmacytosis in acute myeloid leukemia: two cases of plasmacytosis and increased IL-6 production in the AML blast cells. Ann Hematol (1998) 1.07
[Allogeneic transplantation in malignant lymphoma]. Dtsch Med Wochenschr (2001) 1.06
Serum leptin is associated with serum uric acid concentrations in humans. Metabolism (1999) 1.05
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant (2008) 1.05
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol (1997) 1.03
Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia (2013) 1.03
Glucose metabolism rather than insulin is a main determinant of leptin secretion in humans. J Clin Endocrinol Metab (2000) 1.03
Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia (2013) 1.03
Cadmium and lead in the smoke of a filter cigarette. Sci Total Environ (1993) 1.02
Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol (2006) 1.02
Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia (2013) 1.02
Identification of two novel, kinase-deficient variants of discoidin domain receptor 1: differential expression in human colon cancer cell lines. FASEB J (2001) 1.02
Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology (2005) 1.02
Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol (1997) 1.01
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia (2004) 1.01
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia (2011) 1.01